PROLIGHT DIAGNOSTICS
Diagnostics you can count on
RESEARCH
Following the many recent grants, notices of allowance and intention to grant patents in Europe and the US, and the
The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EUR 138 million underscores the growing interest, strategic
The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development
Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation study, including fresh blood samples from 120
Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now
Prolight’s report for Q1’24 did not reveal any particular surprises. The positive SEK 5.6m revision to the FY’23 result stemming
There has been a somewhat mixed news flow from Prolight after the close of Q1’24. The finalization of the cartridge
With proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers even in whole blood, Prolight has taken significant
Having already achieved proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers in low concentrations by counting single
INFO ABOUT PROLIGHT
ANALYST
For new research on growth stocks, sign up to our newsletter